ELISA assays further validated reduced FASN protein levels (p < 0.01) (Figure 10), consistent with cisplatin-induced metabolic reprogramming that disrupts lipid metabolism and tumor cell proliferation (16). This evidence concerns the gene FASN and neoplasm.